211 related articles for article (PubMed ID: 31838573)
1. Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules.
Wang Z; Li K; Chen W; Wang X; Huang Y; Wang W; Wu W; Cai Z; Huang W
Cell Mol Life Sci; 2020 Sep; 77(17):3441-3452. PubMed ID: 31838573
[TBL] [Abstract][Full Text] [Related]
2. Splicing factor SRSF2-centric gene regulation.
Li K; Wang Z
Int J Biol Sci; 2021; 17(7):1708-1715. PubMed ID: 33994855
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
4. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
5. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
6. MiR-155-5p modulates HSV-1 replication via the epigenetic regulation of SRSF2 gene expression.
Wang Z; Li K; Wang X; Huang W
Epigenetics; 2019 May; 14(5):494-503. PubMed ID: 30950329
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients.
Sasidharan Nair V; Saleh R; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Abu Nada M; Elkord E
Epigenomics; 2020 Nov; 12(21):1871-1882. PubMed ID: 33169618
[No Abstract] [Full Text] [Related]
8. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 blockade boosts the expansion of tumor-reactive CD8
Friese C; Harbst K; Borch TH; Westergaard MCW; Pedersen M; Kverneland A; Jönsson G; Donia M; Svane IM; Met Ö
Sci Rep; 2020 Mar; 10(1):3914. PubMed ID: 32127601
[TBL] [Abstract][Full Text] [Related]
10. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
11. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Woroniecka K; Chongsathidkiet P; Rhodin K; Kemeny H; Dechant C; Farber SH; Elsamadicy AA; Cui X; Koyama S; Jackson C; Hansen LJ; Johanns TM; Sanchez-Perez L; Chandramohan V; Yu YA; Bigner DD; Giles A; Healy P; Dranoff G; Weinhold KJ; Dunn GP; Fecci PE
Clin Cancer Res; 2018 Sep; 24(17):4175-4186. PubMed ID: 29437767
[No Abstract] [Full Text] [Related]
12. High CD8
Zhu Q; Yang Y; Deng X; Chao N; Chen Z; Ye Y; Zhang W; Liu W; Zhao S
Front Immunol; 2023; 14():1228004. PubMed ID: 37781365
[TBL] [Abstract][Full Text] [Related]
13. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
14. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
16. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
17. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
18. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
19. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.
Beckermann KE; Hongo R; Ye X; Young K; Carbonell K; Healey DCC; Siska PJ; Barone S; Roe CE; Smith CC; Vincent BG; Mason FM; Irish JM; Rathmell WK; Rathmell JC
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814710
[TBL] [Abstract][Full Text] [Related]
20. Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor β-DAB2IP signals.
Yeh CR; Ou ZY; Xiao GQ; Guancial E; Yeh S
Oncotarget; 2015 Dec; 6(42):44346-59. PubMed ID: 26587829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
